Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.
Learning objectives
- Review the mechanisms responsible for type 2 inflammation found in many chronic inflammatory conditions
- Discuss how microbial dysbiosis in AD is linked to type 2 inflammation, the neuroimmune axis, and skin barrier dysfunction
- Consider how knowledge has advanced our understanding of AD pathophysiology and disease management
Description
In this ADVENT symposium at the 2023 ISID meeting, “Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis”, Masayuki Amagai, MD, PhD (Keio University School of Medicine), Constance Katelaris, MBBS, PhD, FRACP (Campbelltown Hospital), Tilo Biedermann, MD (TUM School of Medicine), and Lisa Beck, MD (University of Rochester Medical Center), reviewed the latest understanding of type 2 inflammation and barrier dysfunction using the latest trial and real-world data, the role of the microbiome and dysbiosis in inflammation and itch, and the type 2 inflammatory mechanisms involved in the pathogenesis of AD.
About these experts
Related resources
